Health & Medical Research
AriBio’s Alzheimer’s Drug AR1001 Slows Decline by 31% in Phase 3 Monotherapy Group, but Misses Overall Trial Endpoint
South Korean biotechnology company AriBio has reported mixed Phase 3 results for AR1001, its investigational once-daily oral candidate for early…